IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$74.48 USD
+0.12 (0.16%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $74.42 -0.06 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for IntraCellular Therapies Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 500 | 594 | 414 | 659 | 224 |
Receivables | 114 | 75 | 20 | 11 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 12 | 24 | 8 | 7 | 0 |
Other Current Assets | 42 | 45 | 25 | 14 | 6 |
Total Current Assets | 668 | 738 | 467 | 691 | 230 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 46 | 0 | 0 | 0 | 0 |
Total Assets | 728 | 755 | 490 | 717 | 251 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 10 | 9 | 6 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 108 | 68 | 38 | 26 | 26 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 124 | 83 | 53 | 37 | 36 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 137 | 99 | 72 | 60 | 56 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,208 | 2,138 | 1,639 | 1,593 | 905 |
Retained Earnings | -1,617 | -1,477 | -1,221 | -937 | -710 |
Other Equity | 0 | -4 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 591 | 656 | 418 | 657 | 195 |
Total Liabilities & Shareholder's Equity | 728 | 755 | 490 | 717 | 251 |
Total Common Equity | 591 | 656 | 418 | 657 | 195 |
Shares Outstanding | 96.20 | 94.70 | 81.40 | 80.10 | 55.40 |
Book Value Per Share | 6.15 | 6.93 | 5.13 | 8.20 | 3.52 |
Fiscal Year End for IntraCellular Therapies Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,025 | 477 | 500 | 495 | 515 |
Receivables | 146 | 131 | 114 | 103 | 96 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 20 | 16 | 12 | 43 | 42 |
Other Current Assets | 74 | 66 | 42 | 62 | 46 |
Total Current Assets | 1,264 | 691 | 668 | 702 | 698 |
Net Property & Equipment | 1 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 40 | 43 | 46 | 0 | 0 |
Total Assets | 1,321 | 747 | 728 | 718 | 714 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 18 | 12 | 11 | 11 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 140 | 120 | 108 | 89 | 81 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 162 | 135 | 124 | 103 | 92 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 176 | 148 | 137 | 117 | 107 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,794 | 2,232 | 2,208 | 2,191 | 2,174 |
Retained Earnings | -1,649 | -1,632 | -1,617 | -1,589 | -1,564 |
Other Equity | -1 | 0 | 0 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,145 | 600 | 591 | 601 | 607 |
Total Liabilities & Shareholder's Equity | 1,321 | 747 | 728 | 718 | 714 |
Total Common Equity | 1,145 | 600 | 591 | 601 | 607 |
Shares Outstanding | 105.50 | 96.80 | 96.20 | 95.90 | 95.90 |
Book Value Per Share | 10.85 | 6.19 | 6.15 | 6.26 | 6.33 |